BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 10, 2009
View Archived Issues
Enzon Offloads Specialty Arm to Sigma-Tau for up to $327M
Enzon Pharmaceuticals Inc. has agreed to sell its specialty pharmaceutical business to Italian-owned Sigma-Tau Pharmaceuticals Inc. for $300 million plus up to an additional $27 million based on milestones. (BioWorld Today)
Read More
Trius and Alimera Join Growing Roster of Biotech IPO Hopefuls
Read More
Twists and Turns Still Ahead for Health Reform after House Vote
Read More
D-Pharm Taking Stroke Drug into China with $25.5M Deal
Read More
Clinic Roundup
Read More
Other News To Note
Read More
ACAAI Roundup
Read More